Cargando…
Phytocannabinoids—A Green Approach toward Non-Alcoholic Fatty Liver Disease Treatment
Non-alcoholic fatty liver disease (NAFLD) is the most frequent chronic liver disease in adults in developed countries, with a global prevalence as high as one billion. The pathogenesis of NAFLD is a multifactorial and multi-step process. Nowadays, a growing body of research suggests the considerable...
Autores principales: | , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7864168/ https://www.ncbi.nlm.nih.gov/pubmed/33498537 http://dx.doi.org/10.3390/jcm10030393 |
_version_ | 1783647614064918528 |
---|---|
author | Berk, Klaudia Bzdega, Wiktor Konstantynowicz-Nowicka, Karolina Charytoniuk, Tomasz Zywno, Hubert Chabowski, Adrian |
author_facet | Berk, Klaudia Bzdega, Wiktor Konstantynowicz-Nowicka, Karolina Charytoniuk, Tomasz Zywno, Hubert Chabowski, Adrian |
author_sort | Berk, Klaudia |
collection | PubMed |
description | Non-alcoholic fatty liver disease (NAFLD) is the most frequent chronic liver disease in adults in developed countries, with a global prevalence as high as one billion. The pathogenesis of NAFLD is a multifactorial and multi-step process. Nowadays, a growing body of research suggests the considerable role of the endocannabinoid system (ECS) as a complex cell-signaling system in NAFLD development. Although increased endocannabinoid tone in the liver highly contributes to NAFLD development, the complex effects and impacts of plant-derived cannabinoids in the aspect of NAFLD pathophysiology are yet not fully understood, and effective medications are still in demand. In our review, we present the latest reports describing the role of ECS in NAFLD, focusing primarily on two types of cannabinoid receptors. Moreover, we sum up the recent literature on the clinical use of natural cannabinoids in NAFLD treatment. This review is useful for understanding the importance of ECS in NAFLD development, and it also provides the basis for more extensive clinical phytocannabinoids testing in patients suffering from NAFLD. |
format | Online Article Text |
id | pubmed-7864168 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-78641682021-02-06 Phytocannabinoids—A Green Approach toward Non-Alcoholic Fatty Liver Disease Treatment Berk, Klaudia Bzdega, Wiktor Konstantynowicz-Nowicka, Karolina Charytoniuk, Tomasz Zywno, Hubert Chabowski, Adrian J Clin Med Review Non-alcoholic fatty liver disease (NAFLD) is the most frequent chronic liver disease in adults in developed countries, with a global prevalence as high as one billion. The pathogenesis of NAFLD is a multifactorial and multi-step process. Nowadays, a growing body of research suggests the considerable role of the endocannabinoid system (ECS) as a complex cell-signaling system in NAFLD development. Although increased endocannabinoid tone in the liver highly contributes to NAFLD development, the complex effects and impacts of plant-derived cannabinoids in the aspect of NAFLD pathophysiology are yet not fully understood, and effective medications are still in demand. In our review, we present the latest reports describing the role of ECS in NAFLD, focusing primarily on two types of cannabinoid receptors. Moreover, we sum up the recent literature on the clinical use of natural cannabinoids in NAFLD treatment. This review is useful for understanding the importance of ECS in NAFLD development, and it also provides the basis for more extensive clinical phytocannabinoids testing in patients suffering from NAFLD. MDPI 2021-01-20 /pmc/articles/PMC7864168/ /pubmed/33498537 http://dx.doi.org/10.3390/jcm10030393 Text en © 2021 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Review Berk, Klaudia Bzdega, Wiktor Konstantynowicz-Nowicka, Karolina Charytoniuk, Tomasz Zywno, Hubert Chabowski, Adrian Phytocannabinoids—A Green Approach toward Non-Alcoholic Fatty Liver Disease Treatment |
title | Phytocannabinoids—A Green Approach toward Non-Alcoholic Fatty Liver Disease Treatment |
title_full | Phytocannabinoids—A Green Approach toward Non-Alcoholic Fatty Liver Disease Treatment |
title_fullStr | Phytocannabinoids—A Green Approach toward Non-Alcoholic Fatty Liver Disease Treatment |
title_full_unstemmed | Phytocannabinoids—A Green Approach toward Non-Alcoholic Fatty Liver Disease Treatment |
title_short | Phytocannabinoids—A Green Approach toward Non-Alcoholic Fatty Liver Disease Treatment |
title_sort | phytocannabinoids—a green approach toward non-alcoholic fatty liver disease treatment |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7864168/ https://www.ncbi.nlm.nih.gov/pubmed/33498537 http://dx.doi.org/10.3390/jcm10030393 |
work_keys_str_mv | AT berkklaudia phytocannabinoidsagreenapproachtowardnonalcoholicfattyliverdiseasetreatment AT bzdegawiktor phytocannabinoidsagreenapproachtowardnonalcoholicfattyliverdiseasetreatment AT konstantynowicznowickakarolina phytocannabinoidsagreenapproachtowardnonalcoholicfattyliverdiseasetreatment AT charytoniuktomasz phytocannabinoidsagreenapproachtowardnonalcoholicfattyliverdiseasetreatment AT zywnohubert phytocannabinoidsagreenapproachtowardnonalcoholicfattyliverdiseasetreatment AT chabowskiadrian phytocannabinoidsagreenapproachtowardnonalcoholicfattyliverdiseasetreatment |